Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alzheimer's Early Approval? Skepticism Over Biogen/Eisai's BAN2401 Data Clouds Chances

Related Content

Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle

Jun 06 2018

Enthusiasm Builds For Biogen’s BAN2401 In Alzheimer's, But SMA Gene Therapy Hits A Snag

Jul 24 2018

Related Companies

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

United States Clinical Trials Drug Approval Standards Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window